CEL-SCI Corporation news

   Watch this stock
Showing stories 1 - 10 of about 87   

Articles published

CVM 1.73 +0.07 (4.22%)
price chart
Cel-Sci Corporation: The Arbitration Is On, But Is The Phase III Trial Off?
I've gone through fur or five significant redrafts of this article since I started trying to get it organized at the end of August, and each time I thought I had captured a good representation of the current situation for Cel-Sci Corp. (NYSEMKT:CVM ...
A Closer Look At Cel-Sci Corporation Going Into Spring Of 2016
Cel-Sci Corporation (NYSEMKT:CVM) is on the verge of several significant milestones and inflection points during the first several months of 2016.
CEL-SCI Corporation Releases Letter to Shareholders
CEL-SCI initiated the proceedings against the former CRO in October 2013 and is seeking payment for damages related to the former CRO's prior involvement in the Phase 3 clinical trial of Multikine.
CEL-SCI Corporation (CVM): Analyzing CEO Compensation
Geert Kersten took the reins as CEL-SCI Corporation's (AMEX:CVM) CEO and earned a total compensation of $629,313 over the past year.
Influential Analyst Rating Changes: CEL-SCI Corporation (NYSEAmerican:CVM ...  Analyst Journal
This Weeks Target Prices For Cel-Sci Corporation (CVM)  NewsDen
CEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development of ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that it has been awarded a new Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Arthritis and Musculoskeletal and Skin ...
Kura Oncology, Inc. (KURA) has a value of $12.50 per share While CEL-SCI ...  Stocks Gallery
Could Cel Sci Corporation (NYSEMKT:CVM) Go Down After Its Newest Short ...  Finance News Daily
CEL-SCI Announces Reverse Stock Split
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announced today that during its annual Shareholder's Meeting on June 12, 2017, a 1-for-25 reverse split was authorized for its outstanding shares of common stock.
CEL-SCI Corp (CVM) Says FDA Requested Changes to Multikine Investigator Brochure
On June 28, 2017 CEL-SCI Corporation received a letter from the U.S. Food and Drug Administration (FDA) in response to CEL-SCI's most recent June 2, 2017 submission regarding the clinical hold imposed on the Company's Phase 3 head and neck cancer ...
CEL-SCI's Manufacturing Of Cancer-Killer Multikine Marks A World-Class Facility
Deep in the state of Maryland, home of the coveted blue crab and picturesque Chesapeake Bay, stands CEL-SCI's (NYSEMKT:CVM) 75,000-square-foot manufacturing facility for Multikine, its exceptional immune-boosting drug geared toward head and neck ...
CEL-SCI Corp (CVM) Announces 1.75M Share Registered Direct Common Offering at ...
CEL-SCI Corporation (NYSE: CVM) today announced it has entered into a definitive agreement with institutional investors for an offering of shares of common stock with gross proceeds of approximately $3.5 million in a registered direct offering.
CEL-SCI Announces $3.5 Million Registered Direct Offering  Business Wire (press release)
A Look Ahead For 2 Stocks: CEL-SCI Corporation (CVM), Triangle Petroleum ...  Post Analyst
Vienna's Cel-Sci Corp. raises $1 million for head and neck cancer trial
Vienna-based drug company Cel-Sci Corp. raised $1 million from institutional investors in a direct offering of 10 million shares, a Securities and Exchange Commission filing this week shows.